| Literature DB >> 25053948 |
Maryam Sotoudeh Anvari1, Mohammad Naderan2, Mohammad Ali Boroumand1, Saeed Shoar2, Robab Bakhshi3, Morteza Naderan3.
Abstract
Aim. To demonstrate the prevalence of isolated organisms in urinary/respiratory tract infections and their antibiotic susceptibilities in a tertiary care center. Methods and Material. Between January 2008 and January 2010, patients referring to the clinic of cardiology or those admitted to the cardiac wards were enrolled in this cross-sectional descriptive study. Urine and sputum sampling was done for all the patients and the specimens underwent microbiologic examination and, in case of isolation of microorganism, antibiotic disk diffusion test was performed. Results. Escherichia coli (E. coli) was the most prevalent isolated organism in-hospital and community-acquired UTIs and was highly resistant to cephalothin in all the samples followed by cotrimoxazole, and ceftriaxone. It revealed high sensitivity to imipenem, amikacin, and nitrofurantoin. Acinetobacter constituted the most prevalent organism isolated from respiratory secretions and represented the highest resistance to ceftriaxone and the greatest sensitivity to imipenem. Conclusions. E. coli and Acinetobacter remain the most common uropathogenic and respiratory organisms, respectively. However, their increasing resistance to wide-spectrum imipenem, meropenem, and vancomycin is a major concern.Entities:
Year: 2014 PMID: 25053948 PMCID: PMC4098766 DOI: 10.1155/2014/682304
Source DB: PubMed Journal: Int J Microbiol
Annual prevalence of microorganisms with the highest frequency.
| Organism | Urine | Organism | Sputum | ||
|---|---|---|---|---|---|
| 2007 | 2008 | 2007 | 2008 | ||
|
| 249 (64%) | 272 (60.9%) |
| 37 (30.8%) | 29 (20.1%) |
|
| 31 (7.9%) | 39 (8.7%) |
| 29 (24.1%) | 26 (18%) |
|
| 26 (6.6%) | 33 (7.3%) |
| 18 (15%) | 52 (36.8%) |
Discriminative prevalence of isolated organism.
| Type of organism | Urine sample | Sputum sample |
|---|---|---|
|
| 5 (0.5%) | 71 (26.8%) |
|
| 10 (1.1%) | 4 (1.5%) |
|
| 521 (62.3%) | 14 (5.3%) |
|
| 37 (4.4%) | 1 (0.4%) |
|
| 23 (2.7%) | 11 (4.1%) |
|
| 59 (7%) | 2 (0.7%) |
|
| 70 (8.3%) | 11 (4.1%) |
|
| 6 (0.7%) | 0 (0) |
|
| 17 (2%) | 66 (25%) |
|
| 12 (1.4%) | 55 (20.8%) |
|
| 29 (3.4%) | 16 (6%) |
|
| 11 (1.3%) | 5 (1.8%) |
|
| 2 (0.2%) | 1 (0.4%) |
|
| 0 (0) | 2 (0.7%) |
|
| 0 (0) | 1 (0.4%) |
|
| 33 (3.9%) | 0 (0) |
Antimicrobial susceptibility pattern of isolated organisms from urine samples.
| Organism | Type of antibiotic | Susceptibility level | ||
|---|---|---|---|---|
| Susceptible | Intermediate | Resistant | ||
|
| Imipenem | 514 (100%) | 0 (0%) | 0 (0%) |
| Amikacin | 483 (94.2%) | 10 (1.9%) | 20 (3.9%) | |
| Nitrofurantoin | 445 (90.1%) | 22 (4.5%) | 27 (5.5%) | |
| Gentamicin | 370 (71.8%) | 23 (4.5%) | 122 (23.7%) | |
| Cefepime | 322 (63%) | 25 (4.9%) | 164 (32.1%) | |
| Ceftazidime | 301 (58.7%) | 21 (4.1%) | 191 (37.2%) | |
| Ceftriaxone | 289 (57%) | 23 (4.5%) | 195 (38.5%) | |
| Ciprofloxacin | 286 (55.6%) | 35 (6.8%) | 193 (37.5%) | |
| Cotrimoxazole | 224 (47.1%) | 17 (3.6%) | 235 (49.4%) | |
| Cephalothin | 145 (28.4%) | 77 (15.1%) | 289 (56.6%) | |
|
| ||||
|
| Imipenem | 57 (100%) | 0 (0%) | 0 (0%) |
| Meropenem | 26 (100%) | 0 (0%) | 0 (0%) | |
| Amikacin | 55 (96.4%) | 0 (0%) | 2 (3.5%) | |
| Ciprofloxacin | 47 (83.9%) | 0 (0%) | 9 (16.1%) | |
| Gentamicin | 46 (80.7%) | 1 (1.8%) | 10 (17.5%) | |
| Cefepime | 41 (71.9%) | 3 (5.3%) | 13 (22.8%) | |
| Ceftazidime | 36 (65.5%) | 1 (1.8%) | 18 (32.7%) | |
| Ceftriaxone | 35 (63.6%) | 4 (7.3%) | 16 (29.1%) | |
| Cotrimoxazole | 34 (63%) | 2 (3.7%) | 18 (33.3%) | |
| Nitrofurantoin | 31 (58.5%) | 8 (15.1%) | 14 (26.4%) | |
| Cephalothin | 30 (54.5%) | 4 (7.3%) | 21 (38.2%) | |
| Ampicillin | 3 (5.6%) | 1 (1.9%) | 50 (92.6%) | |
| Coamoxiclav | 15 (27.3%) | 6 (10.9%) | 34 (61.8%) | |
|
| ||||
|
| Nitrofurantoin | 40 (74.1%) | 5 (9.3%) | 9 (16.7%) |
| Gentamicin | 22 (47.8%) | 3 (6.5%) | 21 (45.7%) | |
| Vancomycin | 26 (44.8%) | 0 (0%) | 32 (55.2%) | |
| Cotrimoxazole | 16 (38.1%) | 2 (4.8%) | 24 (57.1%) | |
| Ciprofloxacin | 19 (35.2%) | 16 (29.4%) | 19 (35.2%) | |
| Erythromycin | 16 (27.6%) | 8 (41.4%) | 34 (58.6%) | |
| Clindamycin | 3 (5.9%) | 0 (0%) | 48 (94.1%) | |
Prevalence of microorganisms isolated from urine samples according to source of infection and time of sampling.
| Admission | Source of infection | |||
|---|---|---|---|---|
| Outpatient | Inpatient | Nosocomial | Community acquired | |
|
| 121 (70.7%) | 400 (60.2%) | 79 (53%) | 321 (62%) |
|
| 21 (12.2%) | 49 (8.7%) | 22 (14.7%) | 38 (7.3%) |
|
| 0 (0) | 54 (8.1%) | 16 (10.7%) | 36 (6.9%) |
|
| 7 (4%) | 0 (0) | 0 (0) | 0 (0) |
Antimicrobial susceptibility pattern of isolated organisms from sputum.
| Organism | Type of antibiotic | Susceptibility level | ||
|---|---|---|---|---|
| Susceptible | Intermediate | Resistant | ||
|
| Vancomycin | 55 (100%) | 0 (0%) | 0 (0%) |
| Clindamycin | 11 (25.6%) | 0 (0%) | 32 (74.4%) | |
| Ciprofloxacin | 8 (24.2%) | 12 (36.4%) | 13 (39.4%) | |
| Erythromycin | 8 (15.4%) | 0 (0%) | 44 (84.6%) | |
| Gentamicin | 4 (13.3%) | 3 (10%) | 23 (76.7%) | |
| Cotrimoxazole | 46 (90.2%) | 0 (0%) | 5 (9.8%) | |
| Cefoxitin | 7 (13.3%) | 2 (3.8%) | 43 (82.7%) | |
|
| ||||
|
| Imipenem | 36 (50.7%) | 1 (1.4%) | 34 (47.9%) |
| Meropenem | 8 (17.8%) | 2 (4.4%) | 35 (77.8%) | |
| Gentamicin | 11 (15.9%) | 1 (1.4%) | 57 (82.6%) | |
| Tobramycin | 6 (14.3%) | 2 (4.8%) | 34 (81%) | |
| Ciprofloxacin | 10 (14.1%) | 7 (9.9%) | 54 (79.1%) | |
| Amikacin | 7 (10.4%) | 2 (3%) | 58 (86.6%) | |
| Cotrimoxazole | 5 (9.3%) | 0 (0%) | 49 (90.7%) | |
| Ceftazidime | 5 (7.4%) | 1 (1.5%) | 62 (91.2%) | |
| Ceftriaxone | 2 (3.2%) | 3 (4.8%) | 58 (92.1%) | |
|
| ||||
|
| Meropenem | 19 (90.5%) | 1 (4.8%) | 1 (4.8%) |
| Ciprofloxacin | 49 (87.5%) | 4 (7.1%) | 3 (5.4%) | |
| Imipenem | 54 (84.4%) | 4 (6.3%) | 6 (9.4%) | |
| Amikacin | 47 (73.4%) | 5 (7.8%) | 12 (18.8%) | |
| Gentamicin | 41 (67.2%) | 1 (1.6%) | 19 (31.1%) | |
| Tobramycin | 36 (66.7%) | 2 (3.7%) | 16 (29.6%) | |
| Ceftazidime | 21 (34.4%) | 1 (1.6%) | 39 (63.9%) | |